首頁 > 市場調查報告書 > 製藥

癌症

市場調查報告書

商品編碼

1712514

全球腫瘤治療市場 - 2025-2033

Global Oncology Therapy Market - 2025-2033

出版日期: 2025年04月22日 | 出版商:

DataM Intelligence | 英文 198 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

2024年全球腫瘤治療市場規模達1,939.8億美元，預計2033年將達到4,402.6億美元，在2025-2033年的預測期內，年複合成長率（CAGR）為9.6%。

腫瘤治療是指旨在管理和治療癌症的醫療治療和介入。它涵蓋了廣泛的治療策略，旨在消除或控制癌細胞、緩解症狀、提高患者的生活品質，並最終在可能的情況下實現緩解或治癒。腫瘤治療是多學科的，通常需要結合多種治療、個人化治療和持續監測。

腫瘤治療是一個廣泛且不斷發展的領域，旨在透過各種方法治療癌症，包括化療、免疫療法、標靶療法、手術和放射治療。這些療法可以組合使用或單獨使用，這取決於癌症的類型和階段。隨著個人化醫療的進步，腫瘤治療的未來在於更精確、更有針對性的治療，以提供更高的療效和更少的副作用。

市場動態：

駕駛員和約束裝置

癌症發生率的上升顯著推動了腫瘤治療市場的成長

癌症在全球範圍內變得越來越常見，其發病率的增加使得對有效治療和療法的需求日益增加。隨著癌症病例的增加，對各種腫瘤療法的需求也日益成長，例如化療、免疫療法、標靶療法和放射療法。越來越多的人被診斷出患有癌症，需要治療的患者數量也隨之增加，導致對現有和新型癌症療法的需求增加。

例如，根據美國國立衛生研究院的數據，癌症是全球主要死亡原因之一。 2022年，全球新增癌症病例近2,000萬，癌症死亡人數達970萬。到2040年，預計每年新發癌症病例數將增加至2,990萬，癌症死亡人數將增加至1,530萬人。根據國際癌症研究機構的預測，2025年全球癌症發生人數將達2,130萬，2030年全球癌症發生人數預計將達2,410萬。

乳癌正成為世界上最嚴重的癌症，發生率和盛行率呈現驚人上升趨勢。例如，根據國際癌症研究機構的預測，預計到 2030 年，全球乳癌發病病例將從 2022 年的 230 萬例增加到近 270 萬例。隨著越來越多的人被診斷出患有癌症，對從化療到先進免疫療法等有效癌症治療的需求日益增加，確保市場持續擴張。

各種腫瘤治療相關的不良反應阻礙了市場成長

雖然腫瘤療法對於癌症治療至關重要，但這些療法的不良反應可能會阻礙其廣泛應用和市場成長。副作用從輕微到嚴重不等，通常會影響患者的生活品質，並可能導致治療中斷或改變。這些不良影響的存在給醫療保健提供者、製藥公司和患者帶來了挑戰，影響了治療決策並限制了市場的潛在成長。

化療是最常見的癌症治療方法之一，但由於其對快速分裂細胞的非選擇性作用，因此會產生多種副作用。它不僅針對癌細胞，還會影響正常健康細胞，導致嚴重的副作用。這些副作用可能導致治療延遲或劑量減少，進而影響治療的整體效果和患者的依從性。因此，患者可能會尋求替代療法或選擇不完成規定的化療方案，阻礙整體市場的成長。

免疫療法雖然在治療黑色素瘤和肺癌等癌症方面具有革命性，但也帶來了一系列獨特的免疫相關不良事件。這些不良影響源自於免疫系統對癌症治療的過度反應，這會導致正常組織和器官出現發炎。標靶治療雖然比傳統化療更精確，但仍會產生與其影響的標靶分子相關的特定副作用。這些療法對於由特定基因突變引起的癌症非常有效，但與抑制這些分子標靶相關的副作用可能會限制它們的使用。

市場領導者和先驅者
- 新興先鋒和傑出參與者
- 擁有最大行銷品牌的既定領導者
- 擁有成熟產品的市場領導者
最新進展與突破
監管和報銷情況
- 北美洲
- 歐洲
- 亞太地區
- 南美洲
- 中東和非洲
波特五力分析
專利分析
SWOT分析
未滿足的需求和差距
市場進入和擴張的推薦策略
情境分析：最佳情況、基本情況和最壞情況預測
定價分析和價格動態

第5章：腫瘤治療市場（依療法分類）

化療
- 烷化劑
- 抗代謝藥
- 抗腫瘤抗生素
- 拓樸異構酶抑制劑
- 其他
標靶治療
- 單株抗體
- 小分子抑制劑
免疫療法
- 免疫檢查點抑制劑（PD-1、PD-L1、CTLA-4）
- CAR-T細胞療法
- 癌症疫苗
- 細胞因子
- 其他
荷爾蒙療法
- 抗雌激素
- 芳香化酶抑制劑
- 黃體生成素釋放激素 (LHRH) 激動劑/拮抗劑
- 其他
放射治療
其他

第6章：腫瘤治療市場（依應用）

乳癌
肺癌
血癌
攝護腺癌
大腸直腸癌
胃癌
肝癌
食道癌
子宮頸癌
卵巢癌
膀胱癌
頭頸癌
皮膚癌（黑色素瘤）
胰腺癌
腎癌
其他

第7章：腫瘤治療市場（依最終使用者分類）

醫院
癌症研究中心
專科診所
其他

第8章：腫瘤治療市場，依區域市場分析與成長機會

北美洲
- 美國
- 加拿大
- 墨西哥
歐洲
- 德國
- 英國
- 法國
- 西班牙
- 義大利
- 歐洲其他地區
亞太
- 中國
- 印度
- 日本
- 韓國
- 亞太其他地區
南美洲
- 巴西
- 阿根廷
- 南美洲其他地區
中東和非洲

第9章：競爭格局與市場定位

競爭概況和主要市場參與者
市佔率分析與定位矩陣
策略夥伴關係、併購
產品組合和創新的關鍵發展
公司基準化分析

第10章：公司簡介

Amgen Inc.

公司概況
產品組合
- 產品描述
- 產品關鍵績效指標 (KPI)
- 歷史和預測產品銷售
- 產品銷售量
財務概覽
- 公司收入
- 地區收入佔有率
- 收入預測
關鍵進展
- 併購
- 關鍵產品開發活動
- 監管部門批准等
SWOT分析

AstraZeneca
Bayer AG
Merck & Co., Inc.
Johnson & Johnson Services, Inc.
F. Hoffmann-La Roche Ltd
Novartis AG
GSK plc
Eli Lilly and Company
Rigel Pharmaceuticals, Inc.

第 11 章：假設與研究方法

資料收集方法
數據三角測量
預測技術
數據驗證和確認

第 12 章：附錄

簡介目錄

Product Code: PH1793

The global oncology therapy market size reached US$ 193.98 billion in 2024 and is expected to reach US$ 440.26 billion by 2033, growing at a compound annual growth rate (CAGR) of 9.6% during the forecast period of 2025-2033.

Oncology therapy refers to the medical treatments and interventions designed to manage and treat cancer. It encompasses a wide range of therapeutic strategies aimed at eliminating or controlling cancer cells, alleviating symptoms, enhancing the patient's quality of life, and ultimately achieving remission or a cure, where possible. Oncology therapy is multi-disciplinary and often requires a combination of treatments, personalized approaches, and ongoing monitoring.

Oncology therapy is a broad and evolving field that aims to treat cancer through various approaches, including chemotherapy, immunotherapy, targeted therapy, surgery, and radiation. These therapies can be used in combination or alone, depending on the type and stage of cancer. With advances in personalized medicine, the future of oncology therapy lies in more precise and tailored treatments that offer higher effectiveness with fewer side effects.

Market Dynamics: Drivers & Restraints

The rising prevalence of cancer is significantly driving the oncology therapy market growth

Cancer is becoming more common globally, and its increasing incidence is creating a heightened demand for effective treatments and therapies. As cancer cases rise, there is a growing need for various oncology therapies, such as chemotherapy, immunotherapy, targeted therapy, and radiation. More people are being diagnosed with cancer, increasing the patient pool requiring treatment, leading to greater demand for both established and novel cancer therapies.

For instance, according to the National Institutes of Health, cancer is among the leading causes of death worldwide. In 2022, there were almost 20 million new cases and 9.7 million cancer-related deaths worldwide. By 2040, the number of new cancer cases per year is expected to rise to 29.9 million and the number of cancer-related deaths to 15.3 million. According to the International Agency for Research on Cancer, in 2025, cancer incidence cases are projected to reach 21.3 million, and in 2030, the cases are estimated to reach 24.1 million.

Breast cancer is becoming the most burdensome cancer in the world, with an alarming rise in incidence and prevalence rate. For instance, according to the International Agency for Research on Cancer projections, nearly 2.7 million breast cancer incidence cases are expected to be reported in 2030, rising from 2.3 million in 2022. With more people being diagnosed, the demand for effective cancer treatments, ranging from chemotherapy to advanced immunotherapies, is intensifying, ensuring continued expansion in the market.

Adverse effects associated with various oncology therapies hamper market growth

While oncology therapies are essential for cancer treatment, adverse effects associated with these therapies can hamper their widespread adoption and market growth. The side effects, which range from mild to severe, often affect patients' quality of life and can lead to treatment discontinuation or modification. The presence of these adverse effects poses challenges for healthcare providers, pharmaceutical companies, and patients, influencing treatment decisions and limiting the market's potential growth.

Chemotherapy is one of the most common cancer treatments, but it is associated with a wide range of toxic side effects due to its non-selective action on rapidly dividing cells. It not only targets cancer cells but also affects normal, healthy cells, leading to significant side effects. These side effects can lead to treatment delays or dose reductions, which can impact the overall efficacy of the therapy and patient compliance. As a result, patients may seek alternative therapies or choose not to complete the prescribed chemotherapy regimen, hindering overall market growth.

Immunotherapy, though revolutionary in treating cancers like melanoma and lung cancer, comes with a unique set of immune-related adverse events. These adverse effects arise from the immune system's overreaction to cancer treatments, which can lead to inflammation in normal tissues and organs. Targeted therapies, while more precise than traditional chemotherapy, still have specific side effects related to the targeted molecules they affect. These therapies can be highly effective for cancers driven by specific genetic mutations, but side effects related to the inhibition of these molecular targets can limit their use.

Segment Analysis

The global oncology therapy market is segmented based on therapy, application, end-user, and region.

Application:

The breast cancer segment is expected to dominate the oncology therapy market with the highest market share

Breast cancer is the most common cancer in women worldwide. The global burden of breast cancer is substantial, and its increasing prevalence drives the demand for effective oncology therapies. For instance, according to the World Health Organization (WHO), in 2022, there were 2.3 million women diagnosed with breast cancer and 670,000 deaths globally, making it the most common cancer across both developed and developing countries.

The advancements in breast cancer treatments are a major driver of the segment's dominance. Over the last few decades, innovations such as targeted therapies, hormonal therapies, and immunotherapies have dramatically improved survival rates and quality of life for breast cancer patients. For instance, targeted therapies like Trastuzumab (Herceptin) have transformed the treatment of HER2-positive breast cancer, leading to improvements in survival for patients.

Novel product launches by major market players in the field of breast cancer are boosting the segment. For instance, in January 2024, AstraZeneca India Pharma Ltd., a science-led biopharmaceutical company, officially launched Trastuzumab deruxtecan, a therapy tailored for the treatment of adult patients with unresectable or metastatic HER2-positive breast cancer for those who have previously received an anti-HER2 regimen. Developed in collaboration with Daiichi Sankyo, Trastuzumab deruxtecan is a specifically engineered HER2-directed antibody drug conjugate (ADC).

Geographical Analysis

North America is expected to hold a significant position in the global oncology therapy market with the highest market share

The oncology therapy market in the North America region is expected to grow owing to the strong presence of major market players, the rising prevalence of cancers, increasing research activities, rising awareness about cancer, rising clinical studies, and well-established healthcare infrastructure. The prevalence of cancer in the United States is continuously rising, which further increases the demand for various oncology therapies. Factors such as aging populations, lifestyle changes, and the prevalence of risk factors like obesity and smoking are driving the demand for improved treatments.

Moreover, the presence of major market players in the region launching various oncology therapies, along with FDA approvals, further accelerates the market growth in the region. For instance, in April 2024, Johnson & Johnson cleared the U.S. Food and Drug Administration (FDA) approval for CARVYKTI (ciltacabtagene autoleucel; cilta-cel) for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least one prior line of therapy, including a proteasome inhibitor and an immunomodulatory agent, and are refractory to lenalidomide. With this approval, CARVYKTI becomes the first and only B-cell maturation antigen (BCMA)-targeted therapy approved for the treatment of patients with multiple myeloma as early as first relapse.

Additionally, in May 2024, Amgen announced that the U.S. Food and Drug Administration (FDA) approved IMDELLTRA (tarlatamab-dlle) for the treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC) with disease progression on or after platinum-based chemotherapy. IMDELLTRA has received accelerated approval based on the encouraging response rate and duration of response (DoR) observed in clinical studies. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).

Competitive Landscape

Top companies in the oncology therapy market include Amgen Inc., AstraZeneca, Bayer AG, Merck & Co., Inc., Johnson & Johnson Services, Inc., F. Hoffmann-La Roche Ltd, Novartis AG, GSK plc, Eli Lilly and Company, Rigel Pharmaceuticals, Inc., and others.

Why Purchase the Report?

Pipeline & Innovations: Reviews ongoing clinical trials, product pipelines, and forecasts upcoming advancements in medical devices and pharmaceuticals.
Product Performance & Market Positioning: Analyzes product performance, market positioning, and growth potential to optimize strategies.
Real-World Evidence: Integrates patient feedback and data into product development for improved outcomes.
Physician Preferences & Health System Impact: Examines healthcare provider behaviors and the impact of health system mergers on adoption strategies.
Market Updates & Industry Changes: Covers recent regulatory changes, new policies, and emerging technologies.
Competitive Strategies: Analyzes competitor strategies, market share, and emerging players.
Pricing & Market Access: Reviews pricing models, reimbursement trends, and market access strategies.
Market Entry & Expansion: Identifies optimal strategies for entering new markets and partnerships.
Regional Growth & Investment: Highlights high-growth regions and investment opportunities.
Supply Chain Optimization: Assesses supply chain risks and distribution strategies for efficient product delivery.
Sustainability & Regulatory Impact: Focuses on eco-friendly practices and evolving regulations in healthcare.
Post-market Surveillance: Uses post-market data to enhance product safety and access.
Pharmacoeconomics & Value-Based Pricing: Analyzes the shift to value-based pricing and data-driven decision-making in R&D.

The global oncology therapy market report delivers a detailed analysis with 62 key tables, more than 69 visually impactful figures, and 198 pages of expert insights, providing a complete view of the market landscape.

Target Audience 2024

Manufacturers: Pharmaceutical, Medical Device, Biotech Companies, Contract Manufacturers, Distributors, Hospitals.
Regulatory & Policy: Compliance Officers, Government, Health Economists, Market Access Specialists.
Technology & Innovation: AI/Robotics Providers, R&D Professionals, Clinical Trial Managers, Pharmacovigilance Experts.
Investors: Healthcare Investors, Venture Fund Investors, Pharma Marketing & Sales.
Consulting & Advisory: Healthcare Consultants, Industry Associations, Analysts.
Supply Chain: Distribution and Supply Chain Managers.
Consumers & Advocacy: Patients, Advocacy Groups, Insurance Companies.
Academic & Research: Academic Institutions.

1. Market Introduction and Scope

1.1. Objectives of the Report
1.2. Report Coverage & Definitions
1.3. Report Scope

2. Executive Insights and Key Takeaways

2.1. Market Highlights and Strategic Takeaways
2.2. Key Trends and Future Projections
2.3. Snippet by Therapy
2.4. Snippet by Application
2.5. Snippet by End-User
2.6. Snippet by Region

3. Dynamics

3.1. Impacting Factors
- 3.1.1. Drivers
  - 3.1.1.1. Rising Prevalence of Cancer
  - 3.1.1.2. Rising Adoption of Combination Therapies
- 3.1.2. Restraints
  - 3.1.2.1. Adverse Effects Associated with Various Oncology Therapies
  - 3.1.2.2. High Cost of Treatment for Oncology Therapy
- 3.1.3. Opportunity
  - 3.1.3.1. Personalized and Precision Oncology
- 3.1.4. Impact Analysis

4. Strategic Insights and Industry Outlook

4.1. Market Leaders and Pioneers
- 4.1.1. Emerging Pioneers and Prominent Players
- 4.1.2. Established Leaders with the Largest Marketing Brand
- 4.1.3. Market Leaders with Established Products
4.2. Latest Developments and Breakthroughs
4.3. Regulatory and Reimbursement Landscape
- 4.3.1. North America
- 4.3.2. Europe
- 4.3.3. Asia Pacific
- 4.3.4. South America
- 4.3.5. Middle East & Africa
4.4. Porter's Five Forces Analysis
4.5. Patent Analysis
4.6. SWOT Analysis
4.7. Unmet Needs and Gaps
4.8. Recommended Strategies for Market Entry and Expansion
4.9. Scenario Analysis: Best-Case, Base-Case, and Worst-Case Forecasts
4.10. Pricing Analysis and Price Dynamics

5. Oncology Therapy Market, By Therapy

5.1. Introduction
- 5.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy
- 5.1.2. Market Attractiveness Index, By Therapy
5.2. Chemotherapy*
- 5.2.1. Introduction
- 5.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
- 5.2.3. Alkylating Agents
- 5.2.4. Antimetabolites
- 5.2.5. Anti-tumor Antibiotics
- 5.2.6. Topoisomerase Inhibitors
- 5.2.7. Others
5.3. Targeted Therapy
- 5.3.1. Monoclonal Antibodies
- 5.3.2. Small Molecule Inhibitors
5.4. Immunotherapy
- 5.4.1. Immune Checkpoint Inhibitors (PD-1, PD-L1, CTLA-4)
- 5.4.2. CAR-T Cell Therapy
- 5.4.3. Cancer Vaccines
- 5.4.4. Cytokines
- 5.4.5. Others
5.5. Hormonal Therapy
- 5.5.1. Anti-estrogens
- 5.5.2. Aromatase Inhibitors
- 5.5.3. Luteinizing Hormone-Releasing Hormone (LHRH) Agonists/Antagonists
- 5.5.4. Others
5.6. Radiation Therapy
5.7. Others

6. Oncology Therapy Market, By Application

6.1. Introduction
- 6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 6.1.2. Market Attractiveness Index, By Application
6.2. Breast Cancer*
- 6.2.1. Introduction
- 6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
6.3. Lung Cancer
6.4. Blood Cancer
6.5. Prostate Cancer
6.6. Colorectal Cancer
6.7. Stomach Cancer
6.8. Liver Cancer
6.9. Esophageal Cancer
6.10. Cervical Cancer
6.11. Ovarian Cancer
6.12. Bladder Cancer
6.13. Head and Neck Cancer
6.14. Skin Cancer (Melanoma)
6.15. Pancreatic Cancer
6.16. Kidney Cancer
6.17. Others

7. Oncology Therapy Market, By End-User

7.1. Introduction
- 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
- 7.1.2. Market Attractiveness Index, By End-User
7.2. Hospitals*
- 7.2.1. Introduction
- 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Cancer Research Centers
7.4. Specialty Clinics
7.5. Others

8. Oncology Therapy Market, By Regional Market Analysis and Growth Opportunities

8.1. Introduction
- 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
- 8.1.2. Market Attractiveness Index, By Region
8.2. North America
- 8.2.1. Introduction
- 8.2.2. Key Region-Specific Dynamics
- 8.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy
- 8.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 8.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
- 8.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 8.2.6.1. U.S.
  - 8.2.6.2. Canada
  - 8.2.6.3. Mexico
8.3. Europe
- 8.3.1. Introduction
- 8.3.2. Key Region-Specific Dynamics
- 8.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy
- 8.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 8.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
- 8.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 8.3.6.1. Germany
  - 8.3.6.2. UK
  - 8.3.6.3. France
  - 8.3.6.4. Spain
  - 8.3.6.5. Italy
  - 8.3.6.6. Rest of Europe
8.4. Asia-Pacific
- 8.4.1. Introduction
- 8.4.2. Key Region-Specific Dynamics
- 8.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy
- 8.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 8.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
- 8.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 8.4.6.1. China
  - 8.4.6.2. India
  - 8.4.6.3. Japan
  - 8.4.6.4. South Korea
  - 8.4.6.5. Rest of Asia-Pacific
8.5. South America
- 8.5.1. Introduction
- 8.5.2. Key Region-Specific Dynamics
- 8.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy
- 8.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 8.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
- 8.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 8.5.6.1. Brazil
  - 8.5.6.2. Argentina
  - 8.5.6.3. Rest of South America
8.6. Middle East and Africa
- 8.6.1. Introduction
- 8.6.2. Key Region-Specific Dynamics
- 8.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy
- 8.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 8.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User

9. Competitive Landscape and Market Positioning

9.1. Competitive Overview and Key Market Players
9.2. Market Share Analysis and Positioning Matrix
9.3. Strategic Partnerships, Mergers & Acquisitions
9.4. Key Developments in Product Portfolios and Innovations
9.5. Company Benchmarking

10. Company Profiles

10.1. Amgen Inc.*
- 10.1.1. Company Overview
- 10.1.2. Product Portfolio
  - 10.1.2.1. Product Description
  - 10.1.2.2. Product Key Performance Indicators (KPIs)
  - 10.1.2.3. Historic and Forecasted Product Sales
  - 10.1.2.4. Product Sales Volume
- 10.1.3. Financial Overview
  - 10.1.3.1. Company Revenue
  - 10.1.3.2. Geographical Revenue Shares
  - 10.1.3.3. Revenue Forecasts
- 10.1.4. Key Developments
  - 10.1.4.1. Mergers & Acquisitions
  - 10.1.4.2. Key Product Development Activities
  - 10.1.4.3. Regulatory Approvals, etc.
- 10.1.5. SWOT Analysis
10.2. AstraZeneca
10.3. Bayer AG
10.4. Merck & Co., Inc.
10.5. Johnson & Johnson Services, Inc.
10.6. F. Hoffmann-La Roche Ltd
10.7. Novartis AG
10.8. GSK plc
10.9. Eli Lilly and Company
10.10. Rigel Pharmaceuticals, Inc.